<DOC>
	<DOCNO>NCT00002256</DOCNO>
	<brief_summary>To provide zalcitabine ( ddC ) patient AIDS Advanced ARC zidovudine ( AZT ) contraindicate , fail treatment intolerant AZT demonstrate ddC monotherapy safe , tolerable patient population .</brief_summary>
	<brief_title>Dideoxycytidine ( Ro 24-2027 ) . A Treatment Protocol Use Dideoxycytidine ( ddC ) Patients With AIDS Advanced ARC Who Can Be Maintained Zidovudine ( AZT ) Therapy .</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Zalcitabine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Aerosolized Pentamidine Trimethoprim/sulfamethoxazole prophylaxis Pneumocystis carinii pneumonia recommend . Dapsone permit discourage . Drugs could cause serious toxicity coadministered study medication allow treatment acute intercurrent illness opportunistic infection investigator 's discretion . Any medication potential cause peripheral neuropathy avoid ; patient consult physician specific drug . Isoniazid permit evidence peripheral neuropathy entry patient take pyridoxine = &gt; 50 mg/day . Metronidazole permit study drug interruption . Patients amphotericin , pyrimethamine , sulfadiazine , trimethoprim/sulfamethoxazole , ganciclovir , intravenous pentamidine , intravenous acyclovir = &gt; 1000 mg/day orally bone marrow renal toxic drug may tolerate concomitant ddC . If drug give concomitantly ddC , patient frequent ( weekly ) laboratory assessment , appropriate . Drugs nephrotoxic potential cause peripheral neuropathy might expect cause increase toxicity coadministered ddC . The following experimental medication allow , judgement investigator , serious additive toxicity anticipate experimental drug necessary optimal patient management : Ampligen , azithromycin , BW 566C80 , bovine colostrum , clarithromycin , diclazuril , foscarnet , oral ganciclovir , GMCSF , GCSF , hypericin , IL2 , interferonbeta , interferongamma , itraconazole , liposomal amphotericin , liposomal gentamicin , nimodipine , PEGIL2 ( polyethylene glycosylated IL2 ) , roxithromycin , spiramycin , trimetrexate . Patients must follow : AIDS Advanced ARC . Patients eligible enter protocol must fall one follow three category : AZT treatment failure AZT intolerance AZT ineligibility Rollover Patients Under 18 year age must consent parent guardian . Exclusion Criteria Patients follow exclude : Any history peripheral neuropathy due cause , even peripheral neuropathy reason discontinuation antiHIV therapy . Any finding suggestive peripheral neuropathy find baseline neurological exam . If patient isolate finding absent achilles reflex may enter sign symptoms finding suggestive peripheral neuropathy . Concomitant treatment exclude medication . Excluded medication include experimental drug ( include ddI ) , drug know nephrotoxic hepatotoxic potential , drug likely cause peripheral neuropathy . Any = &gt; Grade 3 laboratory clinical abnormality severe abnormality list require permission medical monitor enter study.. Unwillingness deem unable sign inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 1994</verification_date>
	<keyword>Zalcitabine</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Zidovudine</keyword>
</DOC>